亚甲基四氢叶酸脱氢酶1-样(MTHFD1L)表达的缺陷仅在少数人类癌症中进行了早期检查。
MTHFD1L作为人类癌症不同亚型的共有生物标志物的多组学分析。
在目前的研究中,用于24种人类癌症主要亚型的MTHFD1L的多组学分析,采用了全面的计算机模拟方法来挖掘不同的开放访问在线数据库,包括UALCAN,卡普兰-迈耶(KM)绘图仪,LOGpc,GEPIA,人蛋白质图谱(HPA),在正常和肿瘤组织中的基因表达(GENT2),MEXPRESS,cBioportal,STRING,大卫,TIMER,和比较毒性基因组学数据库(CTD)。
我们注意到,与正常对照相比,MTHFD1L在所有分析的24种人类癌症亚型中的表达明显更高。此外,MTHDF1L过表达也被发现与膀胱尿路上皮癌(BLCA)的总生存期(OS)持续时间减少显著相关,头颈部肿瘤(HNSC)肾乳头状细胞癌(KIRP),肺腺癌(LUAD),子宫内膜癌(UCEC)。这意味着MTHFD1L在这些癌症的发展和进展中起着重要作用。我们进一步注意到MTHFD1L在BLCA中也过表达,HNSC,KIRP,LUAD,和UCEC患者不同的临床病理特征。通路富集分析显示MTHFD1L相关基因参与五种不同的通路。我们还探索了MTHFD1L表达与其启动子甲基化之间的一些有趣的相关性,遗传改变,CNVs,和CD8+T免疫细胞水平之间。
总之,我们的结果阐明MTHFD1L可以作为BLCA的共同诊断和预后生物标志物,HNSC,KIRP,LUAD,和UCEC患者不同的临床病理特征。
Defects in methylenetetrahydrofolate dehydrogenase 1-like (MTHFD1L) expression have earlier been examined in only a few human cancers.
Multi-omics profiling of MTHFD1L as a shared biomarker in distinct subtypes of human cancers.
In the current study, for the multi-omics analysis of MTHFD1L in 24 major subtypes of human cancers, a comprehensive in silico approach was adopted to mine different open access online databases including UALCAN, Kaplan-Meier (KM) plotter, LOGpc, GEPIA, Human Protein Atlas (HPA), Gene Expression across Normal and Tumor tissue (GENT2), MEXPRESS, cBioportal, STRING, DAVID, TIMER, and Comparative Toxicogenomics Database (CTD).
We noticed that the expression of MTHFD1L was significantly higher in all the analyzed 24 subtypes of human cancers as compared with the normal controls. Moreover, MTHDF1L overexpression was also found to be significantly associated with the reduced overall survival (OS) duration of Bladder urothelial cancer (BLCA), Head and neck cancer (HNSC), Kidney renal papillary cell carcinoma (KIRP), Lung adenocarcinoma (LUAD), and Uterine corpus endometrial carcinoma (UCEC). This implies that MTHFD1L plays a significant role in the development and progression of these cancers. We further noticed that MTHFD1L was also overexpressed in BLCA, HNSC, KIRP, LUAD, and UCEC patients of different clinicopathological features. Pathways enrichment analysis revealed the involvement of MTHFD1L-associated genes in five diverse pathways. We also explored few interesting correlations between MTHFD1L expression and its promoter methylation, genetic alterations, CNVs, and between CD8+ T immune cells level.
In conclusion, our results elucidated that MTHFD1L can serve as a shared diagnostic and prognostic biomarker in BLCA, HNSC, KIRP, LUAD, and UCEC patients of different clinicopathological features.